[Image] From the continuously expanding clinical pipeline to record-breaking BD transactions, the market has cast its vote with real money: ADCs are one of the most imaginative golden tracks in recent years. However, as one pharmaceutical company after another announces the termination of ADC project development or returns rights, this once wildly sought-after track is beginning to show its brutal side. In September of this year, Genmab announced…